Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

Cortés J, Ciruelos E, Pérez-García J, Albanell J, García-Estévez L, Ruiz-Borrego M, Espinosa R, Gallegos I, González S, Álvarez I, Llombart A.

Cancer Treat Rev. 2019 Nov 29;83:101944. doi: 10.1016/j.ctrv.2019.101944. [Epub ahead of print] Review.

PMID:
31830538
2.

Updating the role of obesity and cholesterol in breast cancer.

Garcia-Estevez L, Moreno-Bueno G.

Breast Cancer Res. 2019 Mar 1;21(1):35. doi: 10.1186/s13058-019-1124-1. Review.

3.

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).

Aapro M, Ruiz-Borrego M, Hegg R, Kukielka-Budny B, Morales S, Cinieri S, Freitas-Junior R, Garcia-Estevez L, Szombara E, Borges GS, Passalacqua R, Hervieu H, Groc M, Villanova G.

Breast. 2019 Jun;45:7-14. doi: 10.1016/j.breast.2019.01.009. Epub 2019 Jan 28.

PMID:
30802822
4.

Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies.

Acosta-Eyzaguirre D, Calvo Plaza I, Perelló Martorell A, Hernández Agudo E, García-Estévez L.

Future Oncol. 2018 Mar;14(7s):29-36. doi: 10.2217/fon-2017-0358.

PMID:
29611757
5.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

6.

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.

Hyams DM, Schuur E, Angel Aristizabal J, Bargallo Rocha JE, Cabello C, Elizalde R, García-Estévez L, Gomez HL, Katz A, Nuñez De Pierro A.

J Surg Oncol. 2017 May;115(6):647-662. doi: 10.1002/jso.24561. Epub 2017 Feb 17. Review.

7.

Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.

Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.

Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.

8.

Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.

Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, Sereno M, García-Donás J, Castelo B, Guerra E, Leandro-García LJ, Cascón A, Johansson I, Robledo M, Ingelman-Sundberg M, Rodríguez-Antona C.

Clin Cancer Res. 2015 Jan 15;21(2):322-8. doi: 10.1158/1078-0432.CCR-14-1758. Epub 2014 Nov 14.

9.

Breast cancer management in the elderly.

Luque M, Arranz F, Cueva JF, de Juan A, García-Teijido P, Calvo L, Peláez I, García-Palomo A, García-Mata J, Antolín S, García-Estévez L, Fernández Y.

Clin Transl Oncol. 2014 Apr;16(4):351-61. doi: 10.1007/s12094-013-1113-2. Epub 2013 Oct 2. Review.

PMID:
24085574
10.

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.

Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Review.

PMID:
24071503
11.

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.

Servitja S, Ramos M, Gil M, Sánchez-Rovira P, Vázquez-Estevez S, Virizuela JA, García-Estevez L, Velasco A, Tusquets I.

Anticancer Drugs. 2012 Feb;23(2):239-46. doi: 10.1097/CAD.0b013e32834e2fe4.

PMID:
22112931
12.

SEOM clinical guidelines for the treatment of metastatic breast cancer.

Alvarez López I, de la Haba Rodríguez J, Ruiz Simón A, Bellet Ezquerra M, Calvo Martínez L, García Estévez L, Rodríguez Lescure Á, Isla Casado D; SEOM (Spanish Society for Medical Oncology).

Clin Transl Oncol. 2010 Nov;12(11):719-23.

PMID:
20974562
13.

Current controversies in the management of breast cancer.

Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):278-86. Review. Erratum in: Clin Transl Oncol. 2010 Aug;12(8):581. Muñoz, M [added].

PMID:
20462837
14.

Supportive care for patients with early breast cancer.

García-Estévez L, Tusquets I, Alvarez I, Rodríguez C, Fernández Y, Seguí MA, García-Mata J, Lluch A.

Clin Transl Oncol. 2010 Jan;12(1):32-42. doi: 10.1007/s12094-010-0464-1. Review.

PMID:
20080469
15.

Novel therapeutic approaches to the treatment of metastatic breast cancer.

Fernández Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, García-Mata J, García-Teijido P, Peláez I, García-Estévez L.

Cancer Treat Rev. 2010 Feb;36(1):33-42. doi: 10.1016/j.ctrv.2009.10.001. Epub 2009 Nov 1. Review.

PMID:
19883980

Supplemental Content

Loading ...
Support Center